This company listing is no longer active
Resumen de acción 1LV
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Satsuma Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$8.05 |
| 52 Week Low | US$0.58 |
| Beta | 0.10 |
| 1 Month Change | 7.29% |
| 3 Month Change | 18.39% |
| 1 Year Change | -66.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.88% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 1LV | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | 5.6% | -2.2% | -1.4% |
| 1Y | -67.0% | -27.0% | 2.2% |
Rentabilidad vs. Industria: 1LV underperformed the German Pharmaceuticals industry which returned -10.5% over the past year.
Rentabilidad vs. Mercado: 1LV underperformed the German Market which returned -5.5% over the past year.
Volatilidad de los precios
| 1LV volatility | |
|---|---|
| 1LV Average Weekly Movement | 16.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: 1LV's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 1LV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 25 | John Kollins | www.satsumarx.com |
Resumen de fundamentos de Satsuma Pharmaceuticals, Inc.
| Estadísticas fundamentales de 1LV | |
|---|---|
| Capitalización bursátil | €33.83m |
| Beneficios(TTM) | -€60.14m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.6x
Ratio precio-beneficio (PE)¿Está 1LV sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 1LV | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$64.83m |
| Beneficios | -US$64.83m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.96 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 1LV a largo plazo?
Ver rendimiento histórico y comparativa